Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
All cancer types
Closed
Phase 1
This trial is looking at a drug called GSK2256098 for people who have a that is not responding to other treatment. A solid tumour is any type of cancer, except for leukaemia or lymphoma.
Some types of cancer produce high levels of a protein called focal adhesion kinase or FAK. FAK plays a role in the way cancer grows and spreads. Blocking it may stop cancer spreading.
In this trial, researchers are looking at a drug called GSK2256098 which can block FAK. It is known as a FAK inhibitor.
The aims of this trial are to find out
The highest dose of GSK2256098 you can have safely
What the side effects are
How much of the drug gets into the bloodstream and how long your body takes to get rid of it
If there is something about your cancer that makes it more or less likely to respond to the drug
Recruitment start: 26 July 2010
Recruitment end: 17 April 2013
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Sarah Blagden
Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)
Last reviewed: 16 April 2013
CRUK internal database number: 9586